ThermoGenesis Corporation
2711 Citrus Road
Rancho Cordiva
California
95742
United States
Tel: 916-858-5100
Fax: 916-858-5199
Website: http://www.thermogenesis.com/
194 articles about ThermoGenesis Corporation
-
ThermoGenesis Holdings Announces Financial Results for the Second Quarter Ended June 30, 2021, and Provides Corporate Update
8/12/2021
ThermoGenesis Holdings, Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, reported financial and operating results for the second quarter ended June 30, 2021 and provided a corporate strategic update.
-
ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2021 and Provide a Corporate Strategic Update
8/5/2021
ThermoGenesis Holdings, Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, announced that the Company will release its financial results for the second quarter ended June 30, 2021 and provide a corporate strategic update on Thursday, August 12, 2021, after the close of trading.
-
Cordlife to Use the ThermoGenesis AXP® II System for Rapid Processing of Cord Blood Units in India
6/25/2019
ThermoGenesis Corp. announced that it has entered into a strategic agreement with Cordlife Group Limited to provide its proprietary, next-generation AXP® II System, for the rapid processing of cord blood units, to Cordlife's India processing facility.
-
ThermoGenesis Receives Health Canada Approval of its Next-Generation AXP® II System for Cord Blood Processing
6/18/2019
Marks Second Product Approval from Health Canada This Year
-
ThermoGenesis to Participate in The Orthobiologic Institute's 10th Annual PRP & Regenerative Medicine Symposium
6/5/2019
Company to promote its PXP® cellular processing system
-
ThermoGenesis Releases its Enhanced X-MINI® CD3 Selection Kit for the Research Market
4/17/2019
ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing, today announced the release of the enhanced X-MINI® CD3 Selection Kit for the research market.
-
ThermoGenesis Receives Health Canada Approval of its PXP System for Automated Processing of Bone Marrow Cells
2/25/2019
ThermoGenesis Corp, a private corporation owned by Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing and autologous cell therapies for regenerative medicine, today announced that it received Health Canada approval of its PXP® System for point-of-care harvesting of purified mononuclear cells and platelets from blood or bone marrow.
-
ThermoGenesis Corp Signs Strategic Supply Agreement with Orthohealing Center Management to Provide it's PXP® Point-of-Care System to Orthohealing Method™ Physician Members
2/1/2019
ThermoGenesis Corp., a private corporation owned by Cesca Therapeutics (Nasdaq: KOOL), has entered into a Supply Agreement with Orthohealing Center Management (OCM) that will allow the OCM network of physicians to utilize the ThermoGenesis PXP system to prepare a precise cell concentrate from autologous bone marrow in their office laboratories in order to provide the benefits of their Orthohealing Method to their patients.
-
ThermoGenesis Corp® Completes Construction and Qualification of In-House Clean Room for Assembly of All X-Series™ Cell Processing Disposables
1/21/2019
Transfer from Third Party to In-house Assembly Allows for Greater Control Over Quality, Scale and Costs
-
ThermoGenesis to Announce First Quarter Fiscal 2014 Results on November 14, 2013
11/11/2013
-
ThermoGenesis Axes Jobs in Business Reorg
10/31/2013
-
TotipotentRX & ThermoGenesis Case Study Demonstrates Autologous Stem Cell Product Safely Treats Primary Heart Attack in 60 Minute Clinical Procedure
10/14/2013
-
ThermoGenesis to Present at the Rodman & Renshaw Annual Global Investment Conference
9/3/2013
-
ThermoGenesis Reports Fourth Quarter and Full Fiscal Year 2013 Results
8/30/2013
-
ThermoGenesis to Announce Fourth Quarter and Fiscal 2013 Year End Results on August 29, 2013
8/27/2013
-
TotipotentRX and ThermoGenesis Announce Successful Launch of Bone Marrow Transplant Program
8/8/2013
-
ThermoGenesis and TotipotentRx Form Pact for $18.6 Million
7/16/2013
-
ThermoGenesis Announces New AXP® Customer in the United Kingdom
6/12/2013
-
ThermoGenesis to Announce Third Quarter Fiscal 2013 Results on May 14, 2013
5/7/2013
-
ThermoGenesis Announces New AXP® Customer in Portugal
4/1/2013